More Frequent In-Center Hemodialysis in Pediatric End Stage Renal Disease

NCT ID: NCT01352455

Last Updated: 2013-12-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A health kidney works 24 hours a day, 7 days a week to remove toxins and fluid from the body. Many children with permanent kidney failure undergo dialysis, a life saving procedure that takes the place of a kidney. Currently, many children with permanent kidney failure only receive dialysis treatments 3 days a week in the hospital dialysis clinic. Children on dialysis have a markedly reduced life expectancy, with a life span 40-50 years shorter than their healthy counterparts. Survival for these children has not improved over the last 20 years. These data indicate that the current dialysis treatment strategy is unacceptable.

This research project will study if more frequent dialysis, performed 5 days per week, will improve the health of children with permanent kidney failure compared to the current treatment strategy. Children will be treated with both traditional and more frequent dialysis schedules to measure improvements in their health and well being.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pediatric End Stage Renal Disease Hemodialysis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Hemodialysis Pediatric Outcomes Comparative Effectiveness End Stage Renal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

5 days per week hemodialysis

5 days per week, 2 hours 20 minutes per session versus 3 days per week, 4 hours per session

Group Type EXPERIMENTAL

Hemodialysis

Intervention Type PROCEDURE

5 days per week hemodialysis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hemodialysis

5 days per week hemodialysis

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Current outpatient ESRD pediatric patients, 3-21 years old, receiving in-center chronic HD.
* Patients have to be on chronic HD for at least 2 months before eligibility

Exclusion Criteria

* Patients with a scheduled (with a specific transplant date) kidney transplant in the next 6 months
* Patients scheduled to be switched to peritoneal dialysis in the next 6 months
* Patients currently receiving \>3 days per week of hemodialysis
* Patients currently receiving \>12 hours per week of hemodialysis
* Anyone \<3 years of age would be excluded from the study, so our minimum anticipated patient weight would be about 11 kg
* Patients \>21 years of age at enrollment
* Patients receiving concomitant peritoneal dialysis
* Patients with \<2 months on chronic HD
* Patients with a temporary or femoral dialysis catheter
* Patients who are not hypertensive (both not on blood pressure medication and with a SBP \<95th percentile for age, sex, and height)
* Patients enrolled in an investigational drug trial involving blood pressure medication or any other clinical trial potentially affecting the primary outcome of the study

Patients listed for a deceased donor transplant will not be excluded.
Minimum Eligible Age

3 Years

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Children's Hospital Medical Center, Cincinnati

OTHER

Sponsor Role collaborator

The Hospital for Sick Children

OTHER

Sponsor Role collaborator

Children's Hospital of Philadelphia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Benjamin L Laskin, MD

Role: PRINCIPAL_INVESTIGATOR

Children's Hospital of Philadelphia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cincinnati Childrens Hospital Medical Center

Cincinnati, Ohio, United States

Site Status

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Site Status

The Hospital for Sick Children

Toronto, , Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2010-0596

Identifier Type: -

Identifier Source: org_study_id